Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

DCOY

Decoy Therapeutics Inc

Jan 15 • 01:54PM ET

0.9510

+0.0810 9.31 %

Healthcare • Biotechnology • USA • NASD

Jan 14, 3:01 PMProfit-taking after yesterday's Gates Foundation agreement triggered the sharp intraday decline.

Peers: BLRX ADAP AFMD ANAB IMUX EQ AVIR SYBX CLRB

| Held by: MEDX VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-39.23	Insider Own	6.05%	Shs Outstand	6.38M	Perf Week	23.51%
Market Cap	6.07M	Forward P/E	-	EPS next Y	-	Insider Trans	6.91%	Shs Float	6.03M	Perf Month	21.92%
Enterprise Value	1.26M	PEG	-	EPS next Q	-	Inst Own	4.71%	Short Float	3.06%	Perf Quarter	-79.33%
Income	-5.00M	P/S	-	EPS this Y	-	Inst Trans	6.04%	Short Ratio	0.05	Perf Half Y	-89.66%
Sales	0.00M	P/B	0.21	EPS next Y	-	ROA	-100.54%	Short Interest	0.18M	Perf YTD	46.58%
Book/sh	4.50	P/C	1.26	EPS next 5Y	-	ROE	-139.55%	52W High	52.95 -98.20%	Perf Year	-97.60%
Cash/sh	0.75	P/FCF	-	EPS past 3/5Y	54.55% 57.63%	ROIC	-117.81%	52W Low	0.51 84.73%	Perf 3Y	-99.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	21.71% 13.69%	Perf 5Y	-99.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	68.08%	Oper. Margin	-	ATR (14)	0.17	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	2.79	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.89	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	2.79	EPS Q/Q	84.06%	SMA20	29.29%	Beta	0.39	Target Price	390.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-5.83%	Rel Volume	0.54	Prev Close	0.87
Employees	2	LT Debt/Eq	0.00	Earnings	-	SMA200	-86.06%	Avg Volume	3.70M	Price	0.95
IPO	Jan 29, 2015	Option/Short	No / No	EPS/Sales Surpr.	0.00% -	Trades		Volume	1,389,759	Change	9.31%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-20	Initiated	Ladenburg Thalmann	Buy	$3.80

Jan-13-26 08:15AM	Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform (PR Newswire) +53.37%
Jan-07-26 08:45AM	Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics (GlobeNewswire) +29.23%
Dec-19-25 11:12AM	Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (GlobeNewswire)
Dec-18-25 07:50AM	Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform (GlobeNewswire)
Dec-01-25 08:00AM	Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study (GlobeNewswire) -7.41%
02:42PM	Loading…
Nov-19-25 02:42PM	Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX" (GlobeNewswire) -8.32%
Nov-14-25 05:35PM	Salarius: Q3 Earnings Snapshot (Associated Press Finance) -23.41%
Nov-13-25 08:45AM	Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger (GlobeNewswire) +5.22%
Nov-11-25 09:18AM	Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering (PR Newswire) -51.00%
Oct-13-25 08:45AM	Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements (GlobeNewswire)
Sep-09-25 08:00AM	Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Aug-14-25 08:30AM	Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split (GlobeNewswire) -6.43%
Aug-12-25 05:35PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) -12.04%
Jul-29-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +34.88%
Jul-14-25 08:30AM	Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard (GlobeNewswire) -9.36%
08:30AM	Loading…
Jul-09-25 08:30AM	Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies (GlobeNewswire)
May-14-25 05:33PM	Salarius: Q1 Earnings Snapshot (Associated Press Finance) +11.53%
Apr-16-25 08:00AM	Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board (GlobeNewswire) -6.71%
Mar-26-25 08:00AM	Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses (GlobeNewswire) -9.78%
Mar-24-25 08:00AM	Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-03-25 08:00AM	Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers (GlobeNewswire)
Jan-13-25 08:00AM	Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement (GlobeNewswire) +134.50%
Nov-14-24 07:25PM	Salarius: Q3 Earnings Snapshot (Associated Press Finance)
Aug-09-24 05:21PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) +11.65% -5.22%
Jul-11-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -20.51%
Jun-17-24 08:00AM	Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting (GlobeNewswire)
Jun-12-24 08:00AM	Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split (GlobeNewswire)
May-13-24 10:53PM	SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) -7.12%
04:43PM	Salarius: Q1 Earnings Snapshot (Associated Press Finance)
Mar-22-24 09:52PM	SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace) +5.96% -17.74%
04:34PM	Loading…
04:34PM	Salarius: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-22-24 08:00AM	Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses (GlobeNewswire)
Jan-16-24 08:00AM	Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders (GlobeNewswire)
Jan-03-24 08:30AM	Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment (GlobeNewswire)
Nov-10-23 05:03AM	Salarius: Q3 Earnings Snapshot (Associated Press Finance)
Nov-07-23 08:30AM	Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program (GlobeNewswire)
Aug-10-23 05:10PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) -9.32% -5.92%
04:05PM	Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-09-23 07:39AM	SLRX Pursuing Strategic Alternatives (Zacks) -9.96%
Aug-08-23 04:05PM	Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources (GlobeNewswire)
Jul-11-23 09:00AM	SLRX Continues Cancer Fight with Phase I Trial Approval (Zacks) -12.41%
08:30AM	Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients (GlobeNewswire)
Jun-12-23 08:00AM	Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress (GlobeNewswire)
May-16-23 04:05PM	Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-12-23 08:00AM	Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-11-23 08:20AM	Salarius: Q1 Earnings Snapshot (AP Finance) -5.41%
08:00AM	Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
May-09-23 08:00AM	FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma (GlobeNewswire) -16.20%
07:34AM	SLRX: Fighting Cancer Through Two Paths (Zacks Small Cap Research)
May-01-23 08:30AM	Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 (GlobeNewswire)
Apr-20-23 08:30AM	Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting (GlobeNewswire) -10.75%
Apr-04-23 04:02PM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference (GlobeNewswire) -12.32% -5.48%
12:00PM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023 (GlobeNewswire)
Mar-27-23 08:30AM	Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-15-23 11:00AM	Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia (GlobeNewswire)
Feb-16-23 08:30AM	Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas (GlobeNewswire)
Jan-27-23 08:30AM	Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit (GlobeNewswire) -5.47%
Jan-19-23 08:30AM	Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit (GlobeNewswire) +52.99%
Jan-05-23 08:00AM	Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders (GlobeNewswire)
Dec-13-22 08:01AM	Investigators Present Clinical Data on Salarius Pharmaceuticals Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting (GlobeNewswire) -5.32%
08:00AM	Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-08-22 08:00AM	Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH (GlobeNewswire)
Dec-01-22 08:00AM	Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -5.18%
Nov-10-22 08:30AM	Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-22 09:57AM	Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting (GlobeNewswire)
Oct-27-22 08:30AM	Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference (GlobeNewswire) -14.40%
Oct-19-22 08:30AM	Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference (GlobeNewswire) -15.73%
Oct-18-22 08:30AM	Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -45.18%
Oct-14-22 08:43AM	Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split (GlobeNewswire) -13.81%
Sep-20-22 12:00PM	Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Sep-13-22 08:00AM	Salarius Pharmaceuticals CEO Issues Letter to Stockholders (GlobeNewswire) +10.10%
Aug-22-22 08:30AM	Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewings Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -9.29%
Aug-08-22 08:30AM	Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +9.95%
Aug-04-22 08:30AM	Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire)
Aug-02-22 08:30AM	Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement (GlobeNewswire) -6.07%
Jul-29-22 09:15AM	Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022 (GlobeNewswire)
Jun-09-22 07:33AM	Salarius Pharmaceuticals to Participate in BIO International Convention 2022 (GlobeNewswire)
May-18-22 04:10PM	Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) +20.62% -9.12%
May-12-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results (GlobeNewswire) +38.75% -15.36%
May-11-22 04:05PM	Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration (GlobeNewswire) -16.93%
May-05-22 07:30AM	Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress (GlobeNewswire)
Apr-22-22 08:30AM	Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering (GlobeNewswire) -20.54%
Mar-10-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results (GlobeNewswire) +33.40% -26.62%
Mar-03-22 07:31AM	Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress (GlobeNewswire)
Feb-17-22 08:01AM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference (GlobeNewswire)
Feb-15-22 09:00AM	Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022 (GlobeNewswire)
Feb-08-22 08:00AM	Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference (GlobeNewswire)
Feb-03-22 07:30AM	Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program (GlobeNewswire)
Jan-14-22 01:52PM	Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition (American City Business Journals)
Jan-13-22 07:00AM	Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC (GlobeNewswire)
Jan-06-22 12:45PM	Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022" (GlobeNewswire) -6.06%
Dec-29-21 08:03AM	Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial (GlobeNewswire) -6.19%
Dec-20-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing (PR Newswire)
Dec-15-21 08:31AM	Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum (GlobeNewswire)
Dec-14-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live December 16th (PR Newswire)
Nov-29-21 08:01AM	Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference (GlobeNewswire)
Nov-04-21 04:05PM	Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire) -9.30%
Oct-28-21 03:06PM	Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know (Zacks)

Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HANISH ARNOLD C	Director	Dec 30 '25	Sale	0.64	15	10	5,000	Jan 02 05:13 PM
HANISH ARNOLD C	Director	Dec 30 '25	Sale	0.64	12	8	0	Jan 02 05:13 PM
HANISH ARNOLD C	Director	Nov 20 '25	Buy	0.75	5,000	3,740	5,015	Nov 24 05:08 PM
Rosenblum Mark J	Exec VP Finance, CFO	Nov 20 '25	Buy	0.80	20,000	16,000	20,177	Nov 20 04:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DCOY

Decoy Therapeutics Inc

Upgrade your FINVIZ experience